Immune checkpoint blocker-related sarcoid-like granulomatous inflammation: a rare adverse event detected in lymph node aspiration cytology of patients treated for advanced malignant melanoma

Research output: Contribution to journalArticle

Abstract

Immune checkpoint inhibitors are a major breakthrough in the field of oncology. Targets for approved immune checkpoint inhibitors are cytotoxic T-lymphocytes-associated antigen 4 (CTLA-4) and programmed cell death receptor 1/ programmed cell death ligand 1 (PD-1/PD-L1). Five patients (four males and one female) were treated with immune checkpoint inhibitors for advanced melanoma (stage III). None of them had prior history of autoimmune disorders, AIDS, or sarcoidosis. The PET/CT imaging studies showed new onset lymphadenopathy suspicious for malignancy. Four patients had cutaneous melanoma and one had vaginal melanoma. Three patients were treated with single agent (two Nivolumab, one Ipilimumab) and two with double agents (Ipilimumab and Pembrolizumab, or Ipilimumab and Nivolumab). PET/CT showed mediastinal multistational lymphadenopathy in four cases and peri-portal lymphadenopathy in one patient. Ultrasound-guided fine needle aspiration (FNA) biopsy showed numerous sarcoid-like granulomatous inflammation, while the fungal and mycobacterial infections were excluded. Cytomorphologically, the granulomas were numerous, mostly large, cellular and non-necrotizing. Multi-nucleated giant were rare or not seen at all. Cell blocks did not show any fibrosis. Other adverse effects included mouth sores, flu-like symptoms, arthritis, muscle aches, skin rashes, mild and severe colitis. The treatment was stopped and patients received prednisone. One patient developed severe adrenal insufficiency, which prolonged prednisone tapering. Their condition improved and lymphadenopathy was resolved in follow-up imaging. Sarcoid-like granulomatous inflammation is an adverse event in patients treated with immune checkpoint therapy such as Ipilimumab and Nivolumab. It can present as enlarged lymph nodes in PET/CT imaging suspicious for malignancy. FNA can serve as a minimally invasive tool to investigate the underlying cause of lymphadenopathy in this subset of patients.

Original languageEnglish (US)
Pages (from-to)69-76
Number of pages8
JournalHuman pathology
Volume91
DOIs
StatePublished - Sep 1 2019

Fingerprint

Cell Biology
Melanoma
Lymph Nodes
Inflammation
Fine Needle Biopsy
Prednisone
CD274 Antigen
CTLA-4 Antigen
Adrenal Insufficiency
Death Domain Receptors
Mycoses
Colitis
Sarcoidosis
Exanthema
Granuloma
Arthritis
Mouth
Neoplasms
Acquired Immunodeficiency Syndrome
Fibrosis

Keywords

  • Cytotoxic T lymphocytes–associated antigen 4 (CTLA-4)
  • Fine needle aspiration (FNA)
  • Immune checkpoint blocker
  • Ipilimumab
  • Lymphadenopathy
  • Melanoma
  • Nivolumab
  • Pembrolizumab
  • Programmed cell death receptor 1/ programmed cell death ligand 1 (PD-1/PD-L1)
  • Sarcoid-like granulomatous inflammation

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

@article{0b2caaa310184668bc5f61f9fc972458,
title = "Immune checkpoint blocker-related sarcoid-like granulomatous inflammation: a rare adverse event detected in lymph node aspiration cytology of patients treated for advanced malignant melanoma",
abstract = "Immune checkpoint inhibitors are a major breakthrough in the field of oncology. Targets for approved immune checkpoint inhibitors are cytotoxic T-lymphocytes-associated antigen 4 (CTLA-4) and programmed cell death receptor 1/ programmed cell death ligand 1 (PD-1/PD-L1). Five patients (four males and one female) were treated with immune checkpoint inhibitors for advanced melanoma (stage III). None of them had prior history of autoimmune disorders, AIDS, or sarcoidosis. The PET/CT imaging studies showed new onset lymphadenopathy suspicious for malignancy. Four patients had cutaneous melanoma and one had vaginal melanoma. Three patients were treated with single agent (two Nivolumab, one Ipilimumab) and two with double agents (Ipilimumab and Pembrolizumab, or Ipilimumab and Nivolumab). PET/CT showed mediastinal multistational lymphadenopathy in four cases and peri-portal lymphadenopathy in one patient. Ultrasound-guided fine needle aspiration (FNA) biopsy showed numerous sarcoid-like granulomatous inflammation, while the fungal and mycobacterial infections were excluded. Cytomorphologically, the granulomas were numerous, mostly large, cellular and non-necrotizing. Multi-nucleated giant were rare or not seen at all. Cell blocks did not show any fibrosis. Other adverse effects included mouth sores, flu-like symptoms, arthritis, muscle aches, skin rashes, mild and severe colitis. The treatment was stopped and patients received prednisone. One patient developed severe adrenal insufficiency, which prolonged prednisone tapering. Their condition improved and lymphadenopathy was resolved in follow-up imaging. Sarcoid-like granulomatous inflammation is an adverse event in patients treated with immune checkpoint therapy such as Ipilimumab and Nivolumab. It can present as enlarged lymph nodes in PET/CT imaging suspicious for malignancy. FNA can serve as a minimally invasive tool to investigate the underlying cause of lymphadenopathy in this subset of patients.",
keywords = "Cytotoxic T lymphocytes–associated antigen 4 (CTLA-4), Fine needle aspiration (FNA), Immune checkpoint blocker, Ipilimumab, Lymphadenopathy, Melanoma, Nivolumab, Pembrolizumab, Programmed cell death receptor 1/ programmed cell death ligand 1 (PD-1/PD-L1), Sarcoid-like granulomatous inflammation",
author = "Rodriguez, {Erika F.} and Evan Lipson and Karthik Suresh and Cappelli, {Laura C.} and Monaco, {Sara E.} and Zahra Maleki",
year = "2019",
month = "9",
day = "1",
doi = "10.1016/j.humpath.2019.07.001",
language = "English (US)",
volume = "91",
pages = "69--76",
journal = "Human Pathology",
issn = "0046-8177",
publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - Immune checkpoint blocker-related sarcoid-like granulomatous inflammation

T2 - a rare adverse event detected in lymph node aspiration cytology of patients treated for advanced malignant melanoma

AU - Rodriguez, Erika F.

AU - Lipson, Evan

AU - Suresh, Karthik

AU - Cappelli, Laura C.

AU - Monaco, Sara E.

AU - Maleki, Zahra

PY - 2019/9/1

Y1 - 2019/9/1

N2 - Immune checkpoint inhibitors are a major breakthrough in the field of oncology. Targets for approved immune checkpoint inhibitors are cytotoxic T-lymphocytes-associated antigen 4 (CTLA-4) and programmed cell death receptor 1/ programmed cell death ligand 1 (PD-1/PD-L1). Five patients (four males and one female) were treated with immune checkpoint inhibitors for advanced melanoma (stage III). None of them had prior history of autoimmune disorders, AIDS, or sarcoidosis. The PET/CT imaging studies showed new onset lymphadenopathy suspicious for malignancy. Four patients had cutaneous melanoma and one had vaginal melanoma. Three patients were treated with single agent (two Nivolumab, one Ipilimumab) and two with double agents (Ipilimumab and Pembrolizumab, or Ipilimumab and Nivolumab). PET/CT showed mediastinal multistational lymphadenopathy in four cases and peri-portal lymphadenopathy in one patient. Ultrasound-guided fine needle aspiration (FNA) biopsy showed numerous sarcoid-like granulomatous inflammation, while the fungal and mycobacterial infections were excluded. Cytomorphologically, the granulomas were numerous, mostly large, cellular and non-necrotizing. Multi-nucleated giant were rare or not seen at all. Cell blocks did not show any fibrosis. Other adverse effects included mouth sores, flu-like symptoms, arthritis, muscle aches, skin rashes, mild and severe colitis. The treatment was stopped and patients received prednisone. One patient developed severe adrenal insufficiency, which prolonged prednisone tapering. Their condition improved and lymphadenopathy was resolved in follow-up imaging. Sarcoid-like granulomatous inflammation is an adverse event in patients treated with immune checkpoint therapy such as Ipilimumab and Nivolumab. It can present as enlarged lymph nodes in PET/CT imaging suspicious for malignancy. FNA can serve as a minimally invasive tool to investigate the underlying cause of lymphadenopathy in this subset of patients.

AB - Immune checkpoint inhibitors are a major breakthrough in the field of oncology. Targets for approved immune checkpoint inhibitors are cytotoxic T-lymphocytes-associated antigen 4 (CTLA-4) and programmed cell death receptor 1/ programmed cell death ligand 1 (PD-1/PD-L1). Five patients (four males and one female) were treated with immune checkpoint inhibitors for advanced melanoma (stage III). None of them had prior history of autoimmune disorders, AIDS, or sarcoidosis. The PET/CT imaging studies showed new onset lymphadenopathy suspicious for malignancy. Four patients had cutaneous melanoma and one had vaginal melanoma. Three patients were treated with single agent (two Nivolumab, one Ipilimumab) and two with double agents (Ipilimumab and Pembrolizumab, or Ipilimumab and Nivolumab). PET/CT showed mediastinal multistational lymphadenopathy in four cases and peri-portal lymphadenopathy in one patient. Ultrasound-guided fine needle aspiration (FNA) biopsy showed numerous sarcoid-like granulomatous inflammation, while the fungal and mycobacterial infections were excluded. Cytomorphologically, the granulomas were numerous, mostly large, cellular and non-necrotizing. Multi-nucleated giant were rare or not seen at all. Cell blocks did not show any fibrosis. Other adverse effects included mouth sores, flu-like symptoms, arthritis, muscle aches, skin rashes, mild and severe colitis. The treatment was stopped and patients received prednisone. One patient developed severe adrenal insufficiency, which prolonged prednisone tapering. Their condition improved and lymphadenopathy was resolved in follow-up imaging. Sarcoid-like granulomatous inflammation is an adverse event in patients treated with immune checkpoint therapy such as Ipilimumab and Nivolumab. It can present as enlarged lymph nodes in PET/CT imaging suspicious for malignancy. FNA can serve as a minimally invasive tool to investigate the underlying cause of lymphadenopathy in this subset of patients.

KW - Cytotoxic T lymphocytes–associated antigen 4 (CTLA-4)

KW - Fine needle aspiration (FNA)

KW - Immune checkpoint blocker

KW - Ipilimumab

KW - Lymphadenopathy

KW - Melanoma

KW - Nivolumab

KW - Pembrolizumab

KW - Programmed cell death receptor 1/ programmed cell death ligand 1 (PD-1/PD-L1)

KW - Sarcoid-like granulomatous inflammation

UR - http://www.scopus.com/inward/record.url?scp=85072152563&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072152563&partnerID=8YFLogxK

U2 - 10.1016/j.humpath.2019.07.001

DO - 10.1016/j.humpath.2019.07.001

M3 - Article

C2 - 31279873

AN - SCOPUS:85072152563

VL - 91

SP - 69

EP - 76

JO - Human Pathology

JF - Human Pathology

SN - 0046-8177

ER -